Moderna sues Pfizer and BioNTech over mRNA COVID-19 vaccines
Moderna alleges that Pfizer and BioNTech used its patented mRNA vaccine technologies in the Comirnaty® COVID-19 vaccine without its permission.
List view / Grid view
Moderna alleges that Pfizer and BioNTech used its patented mRNA vaccine technologies in the Comirnaty® COVID-19 vaccine without its permission.
It is difficult to treat cancer effectively without causing adverse side effects. In this article, Dr Li, Clinical Assistant Professor at the State University of New York and Board Director of ExonanoRNA, describes how an old strategy that never got off the ground has finally been leveraged to deliver safe,…
Contract development and manufacturing services for active pharmaceutical ingredients (APIs) must meet the requirements of customers and regulatory bodies alike. In the process control lab of the CARBOGEN AMCIS AG pilot plant in Bubendorf, Switzerland, accurate and efficient Karl Fischer titration workflows for water determination offer fast and reliable decision…
The coronavirus pandemic encouraged biopharmaceutical companies to adopt smarter approaches to vaccine development. Here, Vishnu Kumar and Soundar Kumara from Pennsylvania State University, and Vijay Srinivasan from National Institute of Standards and Technology (NIST), explore the emergence of platform-based vaccine technologies and their potential expansion to treat other life-threatening diseases.
Antibody-drug conjugates (ADCs) are designed to be highly-targeted therapies with the potential to maximise the potency of a treatment while reducing unwanted side effects on healthy tissues. Some 20 years after the first ADC product approval, Dominik Schumacher and Jonas Helma-Smets of Tubulis GmbH discuss how improved and optimised technologies…
Tune in to discover how and why digital twins are being developed and used in pharmaceutical development and manufacturing.
In EPR Issue 4, experts discuss implementing a global strategy to improve the sustainability of endotoxin testing, how to accelerate timelines for manufacture of multi-specific antibodies and the potential of oncolytic viruses as a therapy for glioblastoma. Also featured: progress towards smart vaccine manufacturing, an update on edible anticounterfeiting technology,…
Direct acting antivirals used to treat hepatitis C virus infection may improve symptoms of posttraumatic stress disorder (PTSD) in patients without the disease, according to new research.
Under a collaboration agreement Merck will pay Orna $150 million to support the progress of multiple oRNA vaccine and therapeutic programmes.
Phase III trial results indicate BeiGene’s tislelizumab improved overall survival in patients with unresectable hepatocellular carcinoma (HCC) versus sorafenib.
While thin coatings of copper were found to reduce SARS-CoV-2 viral titers on surfaces, silver had a very limited effect.
Almost half of patients with EGFR-mutated lung cancer with high MET overexpression who had progressed on Tagrisso alone responded to treatment with the addition of savolitinib.
A combination of dexamethasone, remdesivir, and baricitinib was associated with a ‘significant survival benefit’ when compared with dual therapy of dexamethasone with remdesivir, according to a retrospective study.
Phase II results show a high intracranial response rate in breast cancer patients with active brain metastases treated with trastzumab deruxtecan (T-Dxd), an antibody-drug conjugate (ADC).
Alexandre Le Vert, CEO and Co-Founder of Osivax, explores some evolving approaches to vaccine development that aim to counter the effects of virus mutation.